Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority ...

NICE has recommended a new first-line treatment for adults with advanced bladder cancer, marking a significant breakthrough for patients facing this devastating disease.

Women, older people and Black people less likely to receive an SGLT-2 inhibitor prescription for type 2 diabetes ...

Evaluation committee members The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any ...

Seven other digital technologies - Beat Better, Datos Health, Get Ready, Luscii vitals, Pumping Marvellous Cardiac Rehab Platform, R Plus Health and Sword Move - require more research before they can ...

Tarlatamab (IMDYLLTRA, Amgen) is indicated for 'the treatment of adult patients with extensive-stage small-cell lung cancer (ES‑SCLC) with disease progression on or after at least two prior lines of ...

Evidence-based recommendations on tarlatamab (IMDYLLTRA) for treating extensive-stage small-cell lung cancer after 2 or more treatments in adults ...

After considering the feedback from consultation, the appraisal committee has prepared final draft guidance (FDG) on tarlatamab for previously treated advanced small-cell lung cancer [ID6364] and ...

Tarlatamab (Imdylltra) is not normally available on the NHS for treating extensive-stage small-cell lung cancer in adults whose cancer has got worse after 2 or more lines of treatment, including ...

Tarlatamab should not be used to treat extensive-stage small-cell lung cancer in adults whose cancer has progressed after 2 or more lines of treatment, including platinum-based chemotherapy.